急性呼吸窘迫综合征药物治疗的研究进展  

Advances in pharmacological treatment for acute respiratory distress syndrome

作　　者：张可祥[1] 周岐龙 刘超[1] Zhang Kexiang;Zhou Qilong;Liu Chao(Department of Critical Care Medicine,Three Gorges Center Hospital of Chongqing,Chongqing 404000,China)

机构地区：[1]重庆三峡中心医院重症医学科,404000

出　　处：《中国基层医药》2019年第21期2685-2688,共4页Chinese Journal of Primary Medicine and Pharmacy

基　　金：重庆市万州区科学技术委员会科研项目(wzstc-042017072)。

摘　　要：急性呼吸窘迫综合征(ARDS)是常见的危重综合征,其发病率、病死率均较高,治疗措施包括呼吸支持和药物治疗.本文就糖皮质激素、他汀类药物、抗氧化剂、重组人活化蛋白C、镇静剂与肌松剂、外源性肺泡表面活性物质、间充质干细胞、扩血管药物等药物治疗ARDS的最新临床研究进展进行综述.Acute respiratory distress syndrome(ARDS)is a common critical syndrome with high morbidity and mortality.The treatments include respiratory support and drug therapy.In this paper,the latest clinical advances in the treatment of ARDS with glucocorticoids,statins,antioxidants,recombinant human activated protein C,sedatives and muscle relaxants,exogenous alveolar surfactants,mesenchymal stem cells,and vasodilators are reviewed.

关 键 词：呼吸窘迫综合征 成人 药物疗法 糖皮质激素类 西司他汀类 抗氧化剂 肺表面活性物质相关蛋白质类 间质干细胞 血管舒张药 综述 

分 类 号：R47[医药卫生—护理学]